- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
CRIXlabs, Inc. today announced joining the ROCK Health incubator located in San Francisco, CA. CRIXlabs is the creator of NuSilico, the #1 predictive nanoparticle software used by Pharma.
"We couldn't be more excited to be part of the family over at ROCK Health" said Jon Stenstrom, CRIXlabs' CEO and Co-Founder. "CRIXlabs' NuSilico software enables pharmaceutical companies to create more effective treatments with reduced side-effects, for cancer and a wide variety of other diseases." Jon has a strong healthcare product development background and holds a Master of Engineering from San Diego State University.
The CRIXlabs team includes Dr. Shalini Ananda, CTO and Co-Founder with expertise in software development and nanotechnology and Dr. Garrett Smith, Co-Founder and advisor, a serial entrepreneur with expertise in nanoparticle synthesis and a former Stanford BioDesign Fellow; both of which received their PhDs from the University of California, San Diego.
The ROCK Health announcement: rockhealth.com/2013/06/new-class-new-partners-new-space/
About CRIXlabs, Inc.
Creators of NuSilico, the #1 predictive nanoparticle software used by Pharma.
NuSilico increases the probability of finding the next blockbuster drug. Today, Pharma uses NuSilico to identify unfavorable nanotherapeutic candidates early, potentially saving years of development time and millions of dollars. NuSilico can optimize nanoparticle platforms, increasing their ability to treat diseases such as cancer more effectively and with lower side-effects.
CRIXlab’s unique background in software, nanoparticle synthesis, and imaging helps researchers look at all possible scenarios prior to beginning pre-clinical trials.
NuSilico uses a proprietary database and algorithms to determine the biodistribution and half-life of nanoparticle platforms prior to expensive preclinical trials. Early identification helps ensure the research process is efficient and cost-effective for the client.
CRIXlabs has been accepted into the ROCK Health incubator in San Francisco and have terms on the table with Kleiner Perkins, Mohr Davidow, Aberdare Ventures, and the Mayo Clinic.
They have begun working with a Top 10 Pharmaceutical company on their nanoparticle platforms. They are in active discussions with the Top 5 Pharmaceutical companies for the use of their software.
For more information, please click here
Jon Stenstrom, MEng.
Co-Founder & CEO
Copyright © CRIXlabs, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016
Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016
Meteorite impact on a nano scale August 29th, 2016